Volumetric Bioprinting: The New Paradigm in Regenerative Medicine

Creating an object from a scratch: not just an illusion, but a reality. Nowadays, there is a way to turn your ideas into three-dimensional objects and here, the magic word is 3D printing. This technique, also called additive manufacturing, consists of successive layer-by-layer depositions of material which, all together, form the desired object. Contrary to conventional

Read More


Mitochondria–Lysosome Crosstalk: From Physiology to Neurodegeneration

Source Trends in Molecular Medicine Mitochondria and lysosomes are pivotal organelles for cellular metabolism and also have important roles as signaling platforms. Many diseases are characterized by impaired mitochondrial or lysosomal function. These are often referred to as ‘mitochondrial diseases’, which have a primary cause in mitochondria, or as lysosomal storage diseases. Although each specific

Read More


Wyss Institute researchers demonstrate machine-guided engineering of AAV capsids for gene therapy

High-throughput synthetic biology approach reveals hidden AAV features and could help fast-track future gene therapies Adeno-associated viruses (AAVs) have become the go-to vehicle for delivering therapeutic gene cargo to target tissues for the wave of gene therapies that are in development in academic and biotechnology laboratories. However, natural AAVs do not specifically target diseased cells

Read More


BIOLOGICS ALLIANCE™ INITIATES COLLABORATION WITHIN ORTHOPAEDICS COMMUNITY

For the first time, The Arthroscopy Association of North America (AANA), the American Orthopaedic Society for Sports Medicine (AOSSM), the International Cartilage Repair Society (ICRS) and the ON Foundation have collaborated to form The Biologics Alliance (BA)™, an orthopaedic organization dedicated to providing one voice for all matters on musculoskeletal biologics and regenerative medicine. Recently, randomized clinical trials and clinical practice guidelines

Read More


Investment in UK cell and gene therapy manufacturing set to continue

New data released shows cell and gene therapy manufacturing facilities are rapidly becoming operational reflecting job expansion in the sector. Additional 6,000m2 of cell and gene therapy manufacturing space expected to become available within the next 12 months. The Cell and Gene Therapy Catapult (CGT Catapult) published the sixth annual UK cell and gene therapy

Read More